Skip to content
Finance Investment, Medical Health Aged Care

LTR Pharma (ASX:LTP) SPONTAN® Achieves 470% Faster Absorption in Completed Pivotal Study

Jane Morgan Management 2 mins read

Sydney, Australia – 14 October 2024 – LTR Pharma Limited (ASX: LTP) (“LTR Pharma” or “the Company”) is pleased to announce the successful completion of the pivotal clinical study for SPONTAN®, the Company’s novel intranasal formulation of vardenafil for the treatment of erectile dysfunction (ED). The study’s pharmacokinetic and safety data demonstrate SPONTAN’s rapid onset of action and enhanced bioavailability compared to traditional oral ED medications, positioning it as a potential market disruptor in the global ED market.

Key Highlights:

  • 470% Faster Absorption: SPONTAN® achieved a time to maximum plasma concentration (Tmax) of just 12 minutes, compared to 56 minutes for oral vardenafil tablets, representing a 470% faster absorption rate.

  • Comparable Bioavailability: Despite using half the dose, SPONTAN displayed 111.8% dose-normalised bioavailability relative to the oral tablet, indicating clinically relevant comparable efficacy.

  • Higher Peak Concentration: SPONTAN delivered a 155.6% higher peak concentration (Cmax) than the oral tablet, enhancing its potential effectiveness.

  • Favourable Safety Profile: SPONTAN was well-tolerated, with no serious adverse events reported. All treatment-emergent adverse events (TEAEs) were mild to moderate and transient, consistent with the known safety profile of vardenafil.

Comments from the Chief Medical Officer:

Professor Geoffrey Strange, Chief Medical Officer of LTR Pharma, commented:
“These results are highly encouraging from a clinical perspective. The rapid onset of action and pharmacokinetic profile of SPONTAN® have the potential to address significant unmet needs in erectile dysfunction treatment. The speed of absorption, coupled with the excellent bioavailability and safety profile, offers patients a more spontaneous and convenient therapeutic option.”

The study, which involved 18 healthy adult males, used a cross-over design to compare SPONTAN Nasal Spray (5 mg vardenafil) with an oral tablet (10 mg vardenafil). Blood samples were taken at multiple intervals over 24 hours, confirming the significantly faster onset and comparable bioavailability of SPONTAN despite its lower dose.

Regulatory Pathway and Commercialisation:

The positive results from this pivotal study strengthen LTR Pharma's position in ongoing global partnering and licensing discussions. Additionally, the data will support the Company’s engagement with key regulatory bodies, including the US Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA).

Comments from the Chairman:

Lee Rodne, Chairman of LTR Pharma, added:
“These study results mark a significant milestone for LTR Pharma. SPONTAN’s pharmacokinetic profile and rapid onset of action demonstrate its potential to disrupt the global ED market. We are now well-positioned to accelerate our commercialisation strategy, including advancing regulatory discussions and exploring strategic partnerships. This success reinforces our commitment to delivering innovative solutions that can significantly improve patients' lives while creating value for our shareholders.”

Watch how SPONTAN® | Novel Intranasal Technology works here

Learn more: ltrpharma.com


About us:

LTR Pharma is focused on improving men’s health, both physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. LTR Pharma’s lead product, SPONTAN®, is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. SPONTAN works within 10 minutes or less, empowering users with greater control over the timing, spontaneity, and enjoyment of sexual experiences.


Contact details:

For further information, please contact:

Jane Morgan
Investor and Media Relations
Email: jm@janemorganmanagement.com.au

Media

More from this category

  • Medical Health Aged Care, National News Current Affairs
  • 05/11/2024
  • 16:17
National Rural Health Alliance

Unleashing the potential of the rural and remote health workforce

The long-awaited final report Unleashing the Potential of our Health Workforce: Scope of Practice Review was released today following over a year long process to conduct the review in four phases. “The National Rural Health Alliance congratulates the team led by Professor Mark Cormack for this important review which will provide the direction for health policy for many years to come,” said Susi Tegen, Chief Executive of the National Rural Health Alliance. “We are particularly pleased to see the focus on rural and remote barriers highlighted and solutions.” The report provides a number of specific inclusions and recommendations related to…

  • Contains:
  • Medical Health Aged Care
  • 05/11/2024
  • 14:35
Royal Australian College of GPs

GPs warn of worse access and more waste under Scope of Practice recommendations

The Royal Australian College of GPs (RACGP) has urged the Federal Government to exercise caution in its assessment of the recommendations of the Scope of Practice Review report, warning some recommendations will make seeing a GP harder for more patients. The College said some of the report’s recommendations may sound good on the surface but will result in a costlier health system, more delays to care, and higher out-of-pocket costs for patients. The RACGP is particularly concerned about the proposal to open direct referral pathways to more health professionals. RACGP President Dr Nicole Higgins said: “This is a report, not…

  • Contains:
  • Medical Health Aged Care
  • 05/11/2024
  • 13:36
Australian College of Nursing

ACN urges action on key recommendations from Scope of Practice Review

The Australian College of Nursing (ACN) welcomes the findings and recommendations of the Final Report of the Unleashing the Potential of our Health Workforce - Scope of Practice Review, released today by the Minister for Health and Aged Care, the Hon Mark Butler. ACN is urging the Government to respond positively to the recommendations and ‘unleash’ the full potential of nurses and midwives, the largest and most geographically dispersed health profession in Australia. ACN CEO, Professor Kathryn Zeitz FACN, said the Review acknowledges and explains the restrictions, barriers, and inconsistencies across States and Territories that prevent nurses, nurse practitioners, and…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.